Patient and disease characteristics of AYA patients with ALL treated with the C10403 regimen from 2012 to 2020
| . | n (%) . |
|---|---|
| Total cohort | 139 (100) |
| Age at treatment initiation, y | |
| Median (IQR) | 26 (21-32) |
| 17-29 | 92 (66) |
| 30-40 | 47 (34) |
| Sex, male | 96 (69) |
| Race/ethnicity | |
| Non-Hispanic White | 76 (55) |
| Hispanic | 38 (27) |
| Black | 4 (3) |
| Asian | 18 (13) |
| Native American | 1 (1) |
| Hawaiian/Pacific Islander | 2 (1) |
| BMI, kg/m2 | |
| Median (IQR) | 25 (23-31) |
| <25 | 60 (43) |
| 25.0 to <30 | 40 (29) |
| 30 to <35 | 21 (15) |
| ≥35 | 18 (13) |
| ALL immunophenotype | |
| B-ALL | 103 (74) |
| T-ALL | 36 (26) |
| WBC count at diagnosis >30 x 103/μL, B-ALL | 30 (29) |
| WBC count at diagnosis >100 x 103 /μL, T-ALL | 3 (8) |
| High-risk ALL genetics | |
| Ph-like status assessed | 43 (31) |
| Ph-like | 12 (28) |
| Cytogenetics | |
| Hypodiploid | 4 (3) |
| Complex karyotype | 27 (19) |
| KMT2a rearranged | 12 (9) |
| CNS status at diagnosis | |
| CNS1 | 94 (68) |
| CNS2 | 16 (12) |
| CNS3 | 14 (10) |
| Not reported | 15 (11) |
| . | n (%) . |
|---|---|
| Total cohort | 139 (100) |
| Age at treatment initiation, y | |
| Median (IQR) | 26 (21-32) |
| 17-29 | 92 (66) |
| 30-40 | 47 (34) |
| Sex, male | 96 (69) |
| Race/ethnicity | |
| Non-Hispanic White | 76 (55) |
| Hispanic | 38 (27) |
| Black | 4 (3) |
| Asian | 18 (13) |
| Native American | 1 (1) |
| Hawaiian/Pacific Islander | 2 (1) |
| BMI, kg/m2 | |
| Median (IQR) | 25 (23-31) |
| <25 | 60 (43) |
| 25.0 to <30 | 40 (29) |
| 30 to <35 | 21 (15) |
| ≥35 | 18 (13) |
| ALL immunophenotype | |
| B-ALL | 103 (74) |
| T-ALL | 36 (26) |
| WBC count at diagnosis >30 x 103/μL, B-ALL | 30 (29) |
| WBC count at diagnosis >100 x 103 /μL, T-ALL | 3 (8) |
| High-risk ALL genetics | |
| Ph-like status assessed | 43 (31) |
| Ph-like | 12 (28) |
| Cytogenetics | |
| Hypodiploid | 4 (3) |
| Complex karyotype | 27 (19) |
| KMT2a rearranged | 12 (9) |
| CNS status at diagnosis | |
| CNS1 | 94 (68) |
| CNS2 | 16 (12) |
| CNS3 | 14 (10) |
| Not reported | 15 (11) |
CNS1 indicates no blasts present; CNS2 indicates blasts with <5 total WBCs per μL; and CNS3 indicates blast with ≥5 total WBCs per μL.
IQR, interquartile range.